A Gene Transfer Study for Hemophilia A



Status:Recruiting
Conditions:Anemia, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:18 - Any
Updated:3/15/2019
Start Date:December 2016
End Date:December 2019
Contact:Clinical Director
Email:clinicaltrials@sparktx.com

Use our guide to learn which trials are right for you!

Gene Transfer, Dose-Finding Safety, Tolerability, and Efficacy Study of SPK-8011 [a Recombinant Adeno-Associated Viral Vector With Human Factor VIII Gene] in Individuals With Hemophilia A

This clinical research study is being conducted by Spark Therapeutics, Inc. to determine the
safety and efficacy of the factor VIII gene transfer treatment with SPK-8011 in individuals
with hemophilia A.

Hemophilia A is a condition in which blood is unable to clot effectively. It is caused by a
mutation or deletion in the gene that is responsible for producing blood-clotting factor VIII
protein. Individuals with hemophilia A suffer from repeated bleeding episodes, often into the
joints, which can cause chronic joint disease and sometime results in death due to the
inability of the blood to clot efficiently. This chronic joint disease can have significant
physical, psychosocial, and quality-of-life effects, including financial burden. The current
treatment is intravenous (i.v.) injections of factor VIII protein products, either 2-3 times
weekly or in response to bleeding.

Recent preliminary clinical data of a hemophilia B gene transfer study (which is also being
conducted by Spark Therapeutics) shows all study participants achieving therapeutic factor IX
activity levels (average of maintaining factor IX activity levels around 30% of normal with
no confirmed bleeds, after receiving Spark gene transfer, with the approach of using the
novel bio-engineered recombinant adeno-associated viral (rAAV) vector carrying a high
specific activity of a factor IX gene. The approach being tested in this clinical research
study uses a further modified novel AAV vector (with a stronger attraction to the human
liver) to deliver the human factor VIII (hFVIII) gene into liver cells so that they can
produce factor VIII protein.

Inclusion Criteria:

- Males age18 years or older

- Confirmed diagnosis of hemophilia A as evidenced by their medical history with plasma
FVIII activity levels ≤ 2% of normal

- Have received >150 exposure days (EDs) to FVIII concentrates or cryoprecipitate

- Have experienced >10 bleeding events over the previous 12 months only if receiving
on-demand therapy and having FVIII baseline level 1-2% of normal

- Have no prior history of allergic reaction to any FVIII product

- Have no measurable inhibitor against Factor VIII as assessed by the central laboratory
and have no prior history of inhibitors to FVIII protein

- Agree to use reliable barrier contraception

Exclusion Criteria:

- Evidence of active hepatitis B or C

- Currently on antiviral therapy for hepatitis B or C

- Have significant underlying liver disease

- Have serological evidence* of HIV-1 or HIV-2 with CD4 counts ≤200/mm3 (* participants
who are HIV+ and stable with CD4 count >200/mm3 and undetectable viral load are
eligible to enroll)

- Have detectable antibodies reactive with AAV-Spark200 capsid

- Participated in a gene transfer trial within the last 52 weeks or in a clinical trial
with an investigational product within the last 12 weeks
We found this trial at
10
sites
1001 E 5th St
Greenville, North Carolina 27858
(252) 328-6131
Phone: 252-744-1888
East Carolina University Whether it's meeting the demand for more teachers and healthcare professionals or...
?
mi
from
Greenville, NC
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
300 Longwood Ave
Boston, Massachusetts 02115
(617) 355-6000
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
?
mi
from
Boston, MA
Click here to add this to my saved trials
50 Missenden Road
Camperdown, New South Wales 2050
Phone: +029 5656156
?
mi
from
Camperdown,
Click here to add this to my saved trials
?
mi
from
Hershey, PA
Click here to add this to my saved trials
Madison, Mississippi 39110
Phone: 601-499-0935
?
mi
from
Madison, MS
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
Phone: 412-209-7263
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Richmond, Virginia 23235
Phone: 804-827-3306
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Sacramento, California 94817
Phone: 916-734-1293
?
mi
from
Sacramento, CA
Click here to add this to my saved trials